Apple Hopes to Compete With Huawei as it Rolls Out Huge iPhone 15 Discounts in China
| HUGEDelisted Stock | USD 0.09 0 4.56% |
About 61% of FSD Pharma's investor base is looking to short. The analysis of current outlook of investing in FSD Pharma Class suggests that many traders are alarmed regarding FSD Pharma's prospects. The current market sentiment, together with FSD Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use FSD Pharma Class stock news signals to limit their universe of possible portfolio assets.
FSD |
With Apple seeing a decline in iPhone sales in mainland China, the next move is to launch price cuts for the latest models to catch up with Huawei.
Read at techtimes.com
 |
FSD Pharma Fundamental Analysis
We analyze FSD Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FSD Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FSD Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
FSD Pharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
FSD Pharma Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with FSD Pharma stock to make a market-neutral strategy. Peer analysis of FSD Pharma could also be used in its relative valuation, which is a method of valuing FSD Pharma by comparing valuation metrics with similar companies.
Peers
FSD Pharma Related Equities
| LEEEF | Leef Brands | 6.25 | ||||
| MKGAF | MERCK Kommanditgesells | 0.08 | ||||
| BFRI | Biofrontera | 1.89 | ||||
| SXTC | China SXT | 5.13 | ||||
| LOVFF | Cannara Biotech | 9.09 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in FSD Stock
If you are still planning to invest in FSD Pharma Class check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FSD Pharma's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |